Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - Single institute experience

Indian Journal of Medical and Paediatric Oncology

Volumn 32, Issue 2, 2011, Pages 86-91

  Somani, Naresh ^a   Goyal, S ^a   Pasricha, R ^a   Khuteta, N ^a   Agarwal, P ^a   Garg, A ^a   Singhal, H ^a  

^a Bhagwan Mahaveer Cancer Hospital and Research Centre   (India)

Author keywords

Concurrent chemoradiotherapy; Docetaxel Cisplatin 5FU regimen; induction chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INFECTION; INOPERABLE CANCER; LETHARGY; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OBSERVATIONAL STUDY; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 82655177522     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.89781     Document Type: Article

References (17)

1. Garden AS, Asper JA, Morrison WH, Schechter NR,Glisson BS, Kies MS, et al. Is concurrent chemo radiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 2004;100:1171-8. (Pubitemid 38325944)
2. Pignon JP, Bourhis J, Domenge C, Design L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55 (Pubitemid 30148259)
3. Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ,Stack BC Jr, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-8.
4. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-30. (Pubitemid 34787599)
5. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002;25:153-9. (Pubitemid 34293068)
6. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J clin Oncol 1996;14:1762-8
7. Catimel G, Verweji J, Mattijssen V, Hanauske A, Piccart M,Wanders J, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-7.
8. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, et al. Docetaxel, cisplatin, 5-fluorouracil in patients with locally advanced unresectable head and neck;a phase I-II feasibility study. Ann Oncol 2004:15;638-45. (Pubitemid 38559602)
9. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-11. (Pubitemid 29517921)
10. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, fluorouracil and leucovorin (opTPF) as induction for squamous cell carcinoma of the head and neck(SCCHN). Am J Clin Oncol 2002;25:153-9. (Pubitemid 34293068)
11. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C,et al. Docetaxel, cisplatin, fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana Farber Cancer Institute experience. Cancer 2003;97:412-8. (Pubitemid 36133808)
12. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, fluorouracil induction chemotherapy for patients with locally advanced squa Vmous cell cancer of head and neck. J Clin Oncol 2001;19:1096-104. (Pubitemid 32176286)
13. Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesia R,Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704. (Pubitemid 350005151)
14. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin, fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15. (Pubitemid 350005152)
15. Therase P, Arbuck SG, Eisenhauer EA, Wanders J,Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
16. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J,Rizoo A, et al. Phase 3 study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, fluorouracil induction chemotherapy followed by chemo radiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45. (Pubitemid 46211506)
17. Calais G, Pointreau Y, Alfonsi M. Randomized phase 3 trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc Am Soc Clin Oncol 2006;24:281s.